Skip to content

Search

Spatio-temporal spread of artemisinin resistance in Southeast Asia

Current malaria elimination targets must withstand a colossal challenge-resistance to the current gold standard antimalarial drug, namely artemisinin derivatives. If artemisinin resistance significantly expands to Africa or India, cases and malaria-related deaths are set to increase substantially.

Inhibition of macrophage infectivity potentiator in Burkholderia pseudomallei suppresses pro-inflammatory responses in murine macrophages

Melioidosis, caused by the Gram-negative bacterium Burkholderia pseudomallei, is a disease endemic in many tropical countries globally. Clinical presentation is highly variable, ranging from asymptomatic to fatal septicemia, and thus the outcome of infection can depend on the host immune responses. 

Vegetation structure drives mosquito community composition in UK's largest managed lowland wetland

The rising burden of mosquito-borne diseases in Europe extends beyond urban areas, encompassing rural and semi-urban regions near managed and natural wetlands evidenced by recent outbreaks of Usutu and West Nile viruses. While wetland management policies focus on biodiversity and ecosystem services, few studies explore the impact on mosquito vectors.

Tonsils at Telethon: developing a standardised collection of tonsil photographs for group A streptococcal (GAS) research

Group A streptococcus (GAS) infections, such as pharyngitis and impetigo, can lead to rheumatic fever and rheumatic heart disease (RHD). Australian Aboriginal and Torres Strait Islander populations experience high rates of RHD and GAS skin infection, yet rates of GAS pharyngitis are unclear. 

Cohort profile: A population-based record linkage platform to address critical epidemiological evidence gaps in respiratory syncytial virus and other respiratory infections

The Western Australia (WA) Respiratory Infections Linked Data Platform is a population-based cohort established to investigate the epidemiology of RSV and other respiratory infections in children aged 0-10 years, incorporating microbiological testing patterns, hospital admissions, emergency department presentations, and socio-demographic data.

Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study

The Australian Therapeutic Goods Administration approved the use of nirsevimab, a long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV), in November 2023. Western Australia (WA) implemented a combination of nirsevimab administration strategies designed to protect all infants starting in April 2024, before the epidemic season. We developed a dynamic transmission model to predict the impact of WA's RSV immunisation program on infant hospitalisations.

Nirsevimab immunisation of infants and respiratory syncytial virus (RSV)-associated hospitalisations, Western Australia, 2024: a population-based analysis

Christopher Peter Hannah Blyth Richmond Moore MBBS (Hons) DCH FRACP FRCPA PhD MBBS MRCP(UK) FRACP OAM BSc (Hons) GradDipClinEpi PhD Centre Head,

The overlapping global distribution of dengue, chikungunya, Zika and yellow fever

Arboviruses transmitted mainly by Aedes (Stegomyia) aegypti and Ae. albopictus, including dengue, chikungunya, and Zika viruses, and yellow fever virus in urban settings, pose an escalating global threat. Existing risk maps, often hampered by surveillance biases, may underestimate or misrepresent the true distribution of these diseases and do not incorporate epidemiological similarities despite shared vector species.

The relationship between administratively recorded ethnicity and outcomes for people admitted to Australian intensive care units with COVID-19

The relationship between ethnicity and mortality of patients critically ill with COVID-19 in Australia has not been described. Defining those communities at the highest risk of severe COVID-19 may assist with formulating effective public health policy and may improve the equitable delivery of health care in Australia.

Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design

Annual estimates of seasonal influenza vaccine effectiveness can guide global risk communication and vaccination strategies to mitigate influenza-associated illness. We aimed to evaluate vaccine effectiveness in countries using the 2023 southern hemisphere influenza vaccine formulation.